{"id":242932,"date":"2021-09-20T11:58:08","date_gmt":"2021-09-20T11:58:08","guid":{"rendered":"https:\/\/www.thetruthseeker.co.uk\/?p=242932"},"modified":"2021-09-22T07:31:29","modified_gmt":"2021-09-22T07:31:29","slug":"new-fda-records-show-purchases-of-fetal-organs-heads-and-tissue-for-humanized-mice-project","status":"publish","type":"post","link":"https:\/\/www.thetruthseeker.co.uk\/?p=242932","title":{"rendered":"New FDA Records Show Purchases of Fetal Organs, Heads and Tissue for \u2018Humanized Mice\u2019 Project"},"content":{"rendered":"

Judicial Watch \u2013 Sept 14, 2021<\/strong><\/h1>\n
\"\"<\/a>

Aborted human foetuses. Click to enlarge<\/p><\/div>\n

Judicial Watch announced today that it received 198 pages<\/a> of records and communications from the U.S. Food and Drug Administration (FDA) involving \u201chumanized mice<\/a>\u201d research with human fetal heads, organs and tissue, including communications and contracts with human fetal tissue provider Advanced Bioscience Resources (ABR). Most of the records are communications and related attachments between Perrin Larton<\/a>, a procurement manager for ABR, and research veterinary medical officer Dr. Kristina Howard<\/a> of the FDA.<\/p>\n

Judicial Watch received the records through a March 2019 Freedom of Information Act (FOIA) lawsuit<\/a> against the U.S. Department of Health and Human Services, of which the FDA is a part (Judicial Watch v. U.S. Department Health and Human Services<\/em><\/a> (No. 1:19-cv-00876)). The lawsuit asks for all contracts and related documentation on disbursement of funds, procedural documents and communications between FDA and ABR for the provision of human fetal tissue to be used in humanized mice research. After successfully opposing the FDA\u2019s redaction of certain information from its records, a federal court ordered<\/a> HHS to release additional information about its purchases of organs harvested from aborted human fetuses \u2013 including \u201cline item prices,\u201d or the price per organ the government paid to ABR. The court also found \u201cthere is reason to question\u201d whether the transactions violate federal law barring the sale of fetal organs. Documents previously uncovered in this lawsuit show that the federal government demanded the purchased fetal organs be \u201cfresh and never frozen<\/a>.\u201d)<\/p>\n

The records include an FDA generated contract<\/a> with ABR, based on a \u201crequisition\u201d it issued on July 27, 2012, for $12,000 worth of \u201ctissue procurement for humanized mice,\u201d indicates the requisition was for a \u201cnon-competitive award.\u201d Although the initial award was for $12,000, the total estimated amount of funds allocated for the requisition was $60,000. Under \u201cJustification for Other than Full and Open Competition,\u201d the FDA writes:<\/p>\n

Scientists within the FDA and in the larger field of humanized mouse research have searched extensively over the past several years and ABR is the only company in the U.S. capable of supplying tissues suitable for HM research. No other company or organization is capable of fulfilling the need.<\/p>\n

***<\/p>\n

Costs are estimated [for the fetal parts] at $230 per tissue x two tissues per shipment = $460 plus $95 shipping = $555 per shipment. A total of 21 shipments = $11,655.00.<\/p>\n

An April 1, 2013, \u201cAmendment of Solicitation\/Modification of Contract<\/a>\u201d form that shows the FDA purchased fetal livers and thymuses from ABR going back to at least October 2012, billing $580 per liver\/thymus set, but later paying a unit price of $685.<\/p>\n

A January 1, 2013, \u201cFees for Services Schedule<\/a>\u201d provided by ABR to the FDA includes:<\/p>\n

FETAL CADAVEROUS PROCUREMENT\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 SERVICE FEE<\/p>\n

2nd<\/sup> trimester D&E [Dilation and Evacuation abortion] (13-24 weeks) \u00a0\u00a0\u00a0\u00a0\u00a0 per specimen \u00a0\u00a0\u00a0 $275<\/p>\n

1st <\/sup>trimester aspiration [abortion] (8-12 weeks) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 per specimen \u00a0\u00a0\u00a0 $515<\/p>\n

Intact Calvarium [baby\u2019s skull] (8-24 weeks)\u201d \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0 per specimen \u00a0\u00a0\u00a0 $515<\/p>\n

The fees for services schedule also includes \u201cSpecial Processing\/Preservation\u201d of the fetal parts, such as \u201cTissue \u2018Cleaning,\u2019\u201d \u201cSnap freezing\u201d and \u201cPassive freezing (Dry ice).\u201d<\/p>\n

In a September 9, 2014, \u201cOrder for Supplies or Services<\/a>,\u201d the FDA writes regarding a $9,900 order:<\/p>\n

The Contractors shall ship 2nd<\/sup> Trimester thymus $325, 2nd <\/sup>Trimester liver $325. Overnight deliver $150 and EFT wire transfer fee $25, for a total per delivery of $825. Total of this contract not to exceed $9,900.00.<\/p>\n

As the result of an August 21, 2015, \u201cAmendment of Solicitation\/Modification of Contract,\u201d ABR bumped up the price of baby livers and thymuses<\/a> from $325 each to $340 each.<\/p>\n

A \u201cTissue Acquisition Quote<\/a>\u201d sent by ABR to Howard on July 5, 2017, provided a quote of $5,440 each to provide 16 sets of second trimester (16-24 weeks) livers and 16 sets of second trimester (16-24 weeks) thymuses at $340 per \u201csample.\u201d The request for the quote notes that \u201ctissue known to be positive for HIV, HepA, HepB, HepC or chromosomal abnormalities are not acceptable.\u201d<\/p>\n

On June 28, 2017, a redacted FDA contract specialist sends Larton at ABR a request for a quote<\/a> (RFQ) of pricing for human fetal tissue, aged \u201c16-24 weeks,\u201d including a \u201cStatement of Needs\u201d:<\/p>\n

The HM [humanized mice] are created by surgical implantations of human tissue into mice that have multiple genetic mutations that block the development of the mouse immune system at a very early stage. The absence of the mouse immune system allows the human tissues to grow and develop into functional human tissues\u2026. In order for the humanization to proceed correctly we need to obtain fetal tissue with a specific set of specialized characteristics.<\/p>\n

A May 2018, report<\/a> from a company named \u201cLABS,\u201d which was employed by ABR to test fetal parts and their mothers for hepatitis and HIV, notes in its \u201cmethodology description\u201d that they are approved by the FDA \u201cfor living and cadaveric donor screening.\u201d<\/p>\n

The records include a recitation of requirements<\/a> by the FDA for \u201cPayment by Electronic Funds Transfer<\/a>,\u201d in which ABR must adhere to regulations relating to \u201cConvict Labor\u201d and \u201cChild Labor-Cooperation with Authorities and Remedies.\u201d<\/p>\n

On September 24, 2018, the Trump FDA terminated<\/a> its contract with ABR for human tissue purchases and began an audit of its acquisitions of baby body parts. The records include the FDA\u2019s letter terminating<\/a> the contract:<\/p>\n

Based on the terms and conditions of the Purchase Order as awarded to Advanced Bioscience Resources, Inc. (\u201cABR\u201d) on July 27, 2018, the Government is not sufficiently assured that the human tissue provided to the Government to humanize the immune systems of mice will comply with the prohibitions set forth under 42 U.S.C. \u00a7 289g- 2. Furthermore, the Government has concerns with the sufficiency of the sole-source justification. Therefore, pursuant to FAR [Federal Acquisition Regulation] clause 52.213-4(f), the Purchase Order is being terminated effective September 24, 2018.<\/p>\n

\u201cChopping up aborted human beings for their organs and tissue is a moral and legal outrage,\u201d said Judicial Watch President Tom Fitton. \u201cThis issue should be front and center in any debate about America\u2019s barbaric abortion industry.\u201d<\/p>\n

In February 2020, Judicial Watch first uncovered through this lawsuit hundreds of pages of records<\/a> from the National Institutes of Health (NIH) showing that the agency paid thousands of dollars to a California-based firm to purchase organs from aborted human fetuses to create \u201chumanized mice\u201d for HIV research.<\/p>\n

In May 2021, this lawsuit uncovered FDA records<\/a> showing the agency spent tens of thousands of taxpayer dollars to buy human fetal tissue from ABR. The tissue was used in creating \u201chumanized mice\u201d to test \u201cbiologic drug products.\u201d The records indicated the FDA wanted tissue purchases \u201cFresh; shipped on wet ice.\u201d<\/p>\n

On August 3, 2021, Judicial Watch announced<\/a> that it and The Center for Medical Progress<\/a>\u00a0(CMP), through a separate lawsuit, received 252 pages<\/a> of new documents from the U.S. Department of Health and Human Services that reveal nearly $3 million in federal funds were spent on the University of Pittsburgh\u2019s quest to become a \u201cTissue Hub\u201d for human fetal tissue ranging from 6 to 42 weeks\u2019 gestation.\u00a0The Pitt scientists note that, \u201cAll fetal tissue is collected through a collaborative process<\/a>\u00a0including Family Planning, Obstetrics and Pathology.\u201d Pitt anticipated \u201cbeing able to\u00a0harvest and distribute<\/a>\u00a0quality tissue and cells \u2026 [and] do not anticipate any major problems related to the acquisition and distribution of the tissues.\u201d Pitt\u2019s target goal<\/a> \u201cis to have available a minimum of 5 cases (tissues and if possible other biologicals) per week of gestational age for ages 6-42 weeks.\u201d<\/p>\n

Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

What kind of \u2018Frankenstein science\u2019 uses the heads and organs from aborted human foetuses? <\/p>\n","protected":false},"author":39262,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[23,71],"tags":[],"class_list":["post-242932","post","type-post","status-publish","format-standard","hentry","category-Fringe_Science_New_Discoveries_and_Developments","category-Health_and_the_New_World_Order"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/242932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=\/wp\/v2\/users\/39262"}],"replies":[{"embeddable":true,"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=242932"}],"version-history":[{"count":3,"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/242932\/revisions"}],"predecessor-version":[{"id":242935,"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=\/wp\/v2\/posts\/242932\/revisions\/242935"}],"wp:attachment":[{"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=242932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=242932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.thetruthseeker.co.uk\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=242932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}